Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inezetamab
- Development stage
- Phase 1
- Lead developer
- Amgen
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AMG 994 (inezetamab) is a bispecific antibody developed for the treatment of advanced solid tumors. It is designed to target two as-yet-undisclosed antigens and exhibits potential antineoplastic activity by inhibiting tumor cell proliferation. The drug has been evaluated as both monotherapy and in combination with the anti-PD-1 antibody zeluvalimab (AMG 404) in patients with advanced solid tumors expressing mesothelin, including mesothelioma, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma, and high-grade serous ovarian carcinoma. Its mechanism of action involves binding to two targets on tumor cells; however, the specific targets have not been publicly disclosed[1][2][6]. Development has reached phase I clinical trials[2][3][4][7].
- Other names
- inezetamabAMG 994AMG994AMG-994
02
Targets
CD40 (Cluster of differentiation 40 receptor)Mesothelin
Beyond the preview
Go deeper on inezetamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inezetamab.